• Je něco špatně v tomto záznamu ?

Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study

M. Ashina, DD. Mitsikostas, FM. Amin, P. Kokturk, CJ. Schankin, G. Sahin, P. Pozo-Rosich, PJ. Dorman, T. Nežádal, AC. Poole, IP. Martins, ML. Sumelahti, V. Ramirez Campos, AH. Ahn, L. Lyras, C. Tassorelli

. 2023 ; 43 (11) : 3331024231214987. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu pozorovací studie, klinické zkoušky, fáze IV, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000765

BACKGROUND: The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine. This interim analysis reports primary, secondary and exploratory endpoints from when 500 participants completed at least six months of treatment. METHODS: Adults with episodic migraine or chronic migraine maintaining daily headache diaries were enrolled upon initiation of fremanezumab. Primary endpoint: proportion of participants with ≥50% reduction in monthly migraine days during the six-month period after fremanezumab initiation. Secondary endpoints: mean change from baseline across months 1-12 in monthly migraine days, acute migraine medication use, and headache-related disability. Exploratory endpoint: mean change in headache severity from baseline across months 1-12. Safety was assessed through adverse events reported. RESULTS: Overall, 897 participants were enrolled and 574 included in the effectiveness analyses (episodic migraine, 25.8%; chronic migraine, 74.2%). Of participants with data available, 175/313 (55.9%) achieved ≥50% monthly migraine days reduction during the six-month period post-initiation. Across months 1-12, there were sustained reductions in mean monthly migraine days, acute medication use, disability scores, and headache severity. Few adverse events were reported. CONCLUSION: PEARL interim results support the effectiveness and safety of fremanezumab for migraine prevention in a real-world population across several European countries.Trial registration: encepp.eu: EUPAS35111.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000765
003      
CZ-PrNML
005      
20240213093350.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/03331024231214987 $2 doi
035    __
$a (PubMed)37987641
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ashina, Messoud $u Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
245    10
$a Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study / $c M. Ashina, DD. Mitsikostas, FM. Amin, P. Kokturk, CJ. Schankin, G. Sahin, P. Pozo-Rosich, PJ. Dorman, T. Nežádal, AC. Poole, IP. Martins, ML. Sumelahti, V. Ramirez Campos, AH. Ahn, L. Lyras, C. Tassorelli
520    9_
$a BACKGROUND: The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine. This interim analysis reports primary, secondary and exploratory endpoints from when 500 participants completed at least six months of treatment. METHODS: Adults with episodic migraine or chronic migraine maintaining daily headache diaries were enrolled upon initiation of fremanezumab. Primary endpoint: proportion of participants with ≥50% reduction in monthly migraine days during the six-month period after fremanezumab initiation. Secondary endpoints: mean change from baseline across months 1-12 in monthly migraine days, acute migraine medication use, and headache-related disability. Exploratory endpoint: mean change in headache severity from baseline across months 1-12. Safety was assessed through adverse events reported. RESULTS: Overall, 897 participants were enrolled and 574 included in the effectiveness analyses (episodic migraine, 25.8%; chronic migraine, 74.2%). Of participants with data available, 175/313 (55.9%) achieved ≥50% monthly migraine days reduction during the six-month period post-initiation. Across months 1-12, there were sustained reductions in mean monthly migraine days, acute medication use, disability scores, and headache severity. Few adverse events were reported. CONCLUSION: PEARL interim results support the effectiveness and safety of fremanezumab for migraine prevention in a real-world population across several European countries.Trial registration: encepp.eu: EUPAS35111.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    12
$a monoklonální protilátky $7 D000911
650    12
$a migréna $x farmakoterapie $x prevence a kontrola $7 D008881
650    _2
$a bolesti hlavy $7 D006261
655    _2
$a pozorovací studie $7 D064888
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mitsikostas, Dimos D $u First Department of Neurology, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Amin, Faisal Mohammad $u Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark $u Department of Neurorehabilitation/Traumatic Brain Injury, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Kokturk, Pinar $u Teva Netherlands B.V., Amsterdam, Netherlands
700    1_
$a Schankin, Christoph J $u Department of Neurology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland $1 https://orcid.org/0000000346686098
700    1_
$a Sahin, Gurdal $u Department of Clinical Sciences of Lund, Lund University, Skåneuro Neurology Clinic, Lund, Sweden
700    1_
$a Pozo-Rosich, Patricia $u Headache Unit & Research Group, Vall d'Hebron Hospital & Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000307964702
700    1_
$a Dorman, Paul J $u The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
700    1_
$a Nežádal, Tomáš $u Institute of Neuropsychiatric Care, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Poole, Anne Christine $u Private Practice: Oslo Headache Centre, Oslo, Norway
700    1_
$a Martins, Isabel Pavão $u Centro de Estudos Egas Moniz, Faculty of Medicine, University of Lisbon, Lisbon, Portugal $1 https://orcid.org/0000000296117400
700    1_
$a Sumelahti, Marja-Liisa $u Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland $1 https://orcid.org/0000000165810483
700    1_
$a Ramirez Campos, Verena $u Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
700    1_
$a Ahn, Andrew H $u Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
700    1_
$a Lyras, Leonidas $u Teva Netherlands B.V., Amsterdam, Netherlands
700    1_
$a Tassorelli, Cristina $u Department of Brain & Behavioral Sciences, University of Pavia, Pavia, Italy $u IRCCS Mondino Foundation, Pavia, Italy $1 https://orcid.org/0000000315132113
773    0_
$w MED00001084 $t Cephalalgia $x 1468-2982 $g Roč. 43, č. 11 (2023), s. 3331024231214987
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37987641 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093347 $b ABA008
999    __
$a ok $b bmc $g 2049409 $s 1210459
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 43 $c 11 $d 3331024231214987 $e - $i 1468-2982 $m Cephalalgia $n Cephalagia $x MED00001084
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace